Drug Profile
SiLi D1
Alternative Names: Silibinin D1; SiLiD1Latest Information Update: 24 Apr 2007
Price :
$50
*
At a glance
- Originator Unknown
- Developer AMC Cancer Research Center; Oncology Sciences Corporation
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 15 Aug 2003 SiLi D1 is available for licensing (http://www.oncologysciences.com)
- 05 Dec 2002 This compound is still in active development